Volume 27, Number 2—February 2021
Research Letter
Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020
Sitanshu Sekhar Kar
, Sonali Sarkar, Sharan Murali, Rahul Dhodapkar, Noyal Mariya Joseph, and Rakesh Aggarwal
, Sonali Sarkar, Sharan Murali, Rahul Dhodapkar, Noyal Mariya Joseph, and Rakesh Aggarwal
Table
Seroprevalence of SARS-CoV-2 antibodies in 3 surveys in Puducherry, India, 2020*
| Variable | August 11–16, n = 869 |
September 10–16, n = 898 |
October 12–16, n = 900 |
|||||
|---|---|---|---|---|---|---|---|---|
| No, positive/ no. tested | % (95% CI) | No. positive/ no. tested | % (95% CI) | No. positive/ no. tested | % (95% CI) | |||
| Crude prevalence |
43/869 |
4.9 (3.5–6.4) |
186/898 |
20.7 (18.0–23.3) |
311/900 |
34.5 (31.5–37.7) |
||
| Age category, y | ||||||||
| 18–29 | 8/170 | 4.7 (1.5–7.8) | 33/165 | 20.0 (13.9–26.1) | 58/180 | 32.2 (25.8–39.3) | ||
| 30–44 | 13/295 | 4.4 (2.1–6.7) | 58/277 | 20.9 (16.2–25.7) | 92/252 | 36.5 (30.8–42.6) | ||
| 45–59 | 13/242 | 5.4 (2.5–8.2) | 64/271 | 23.6 (18.5–28.7) | 101/259 | 39.0 (33.2–45.0) | ||
| >60 |
9/162 |
5.6 (2.0–9.1) |
31/185 |
16.7 (11.4–22.1) |
60/209 |
28.7 (23.0–35.1) |
||
| Sex | ||||||||
| M | 16/439 | 3.6 (1.9–5.4) | 95/443 | 21.4 (17.6–25.2) | 126/406 | 31.0 (26.7–35.6) | ||
| F |
27/428 |
6.3 (4.0–8.6) |
91/455 |
20.0 (16.3–23.6) |
183/491 |
37.2 (33.1–41.6) |
||
| Residence setting† | ||||||||
| Urban | 35/609 | 5.7 (3.9–7.5) | 130/629 | 20.7 (17.5–23.8) | 225/628 | 35.8 (32.1–39.7) | ||
| Rural |
8/260 |
3.1 (1.0–5.2) |
56/269 |
20.8 (16.0–25.7) |
86/272 |
31.6 (26.3–37.4) |
||
| Occupation‡ | ||||||||
| Healthcare workers | 2/29 | 6.9 (1.0–22.8) | 4/32 | 12.5 (1.0–24.0) | 18/66 | 27.2 (18.0–39.0) | ||
| Other frontline workers | 0/22 | 0 | 8/23 | 34.8 (15.3–54.2) | 6/15 | 40.0 (19.0–64.2) | ||
| Others |
41/818 |
5.0 (3.5–6.5) |
174/843 |
20.6 (17.9–23.4) |
287/819 |
35.0 (31.8–38.3) |
||
| Other characteristics | ||||||||
| COVID-19 | 4/34 | 11.8 (9.3–22.6) | 16/47 | 34.0 (20.5–47.6) | 82/184 | 44.5 (37.5–51.7) | ||
| COVID-19 diagnosis | 3/3 | 100 | 3/7 | 42.9 (6.1–79.5) | 25/29 | 86.2 (69.4–94.5) | ||
| COVID-19 symptoms in last 6 mo |
8/85 |
9.4 (3.2–15.6) |
10/44 |
22.7 (10.3–35.1) |
85/148 |
57.4 (49.3–65.1) |
||
| Cumulative case incidence (cumulative incidence ratio)§ |
2,987 (0.25%) |
12,331 (1.03%) |
23,080 (1.92%) |
|||||
| Infection-to-case ratio¶ |
4.9%/0.25% = 19.6 |
20.9%/1.03% = 20.0 |
34.5%/1.92% = 18.0 |
|||||
| Cumulative deaths |
43 |
187 |
441 |
|||||
| Infection fatality ratio (cumulative deaths per 100,000 infected persons)# | 73.4 |
75.8 |
106.1 |
|||||
*COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Definitions used by the Office of the Registrar General & Census Commissioner, Government of India. ‡Other frontline workers included police officers, teachers, revenue officers, persons involved in COVID-19 response. §Calculated for data gathered until 2 weeks before the midpoint of the survey. ¶Infection-to-case ratio was calculated as crude seroprevalence / cumulative incidence ratio. #Infection-fatality ratio was calculated as cumulative deaths/crude prevalence × estimated population of the district.
Page created: December 10, 2020
Page updated: January 24, 2021
Page reviewed: January 24, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.